Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Learn how we applied our expertise of over 2 million cfDNA tests performed by quantifying background cfDNA to refine risk of rejection in your transplant patients.

Now Quantify the Risk: Run a cfDNA Background Check Every Time